

Applicant: Wilson

Application No.: 10/589,931

Amendment and Response dated November 30, 2009

Reply to Office Action dated May 28, 2009

Docket No.: 1567-7 PCT/US

Page 3

AMENDMENTS TO THE CLAIMS

The following list of claims will replace all prior versions, and listings, of claims. Please amend the claims as follows:

1. (currently amended) A method of isolating plasma from a canine animal including the steps of:
 - (I) selecting a donor canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group, wherein the donor canine animal is selected for a phenotype lacking anti-globulin antibodies;
 - (II) (II)—collecting blood from the donor canine animal after administering a heat-killed *E. coli* antigen to said donor canine animal; and
 - (III) isolating plasma from blood collected in step (II).
2. (currently amended) The method of claim 1 wherein the donor canine animal is selected for a phenotype lacking at least one Dog Erythrocyte Antigen.
3. (currently amended) The method of claim 2 wherein the donor canine animal is negative for Dog Erythrocyte Antigen 1.1.
4. (currently amended) The method of claim 3 wherein the donor canine animal is negative for Dog Erythrocyte Antigen 1.2.
5. (currently amended) The method of claim 4 wherein the donor canine animal is negative for Dog Erythrocyte Antigen 7.
6. (cancelled)

Applicant: Wilson

Application No.: 10/589,931

Amendment and Response dated November 30, 2009

Reply to Office Action dated May 28, 2009

Docket No.: 1567-7 PCT/US

Page 4

7. (currently amended) The method of claim 1 ~~further including wherein step (II) further includes~~ the steps of:

- (a) inserting a blood collecting catheter into a vein of the donor canine animal;
- (b) attaching the blood collecting catheter to a cell separator capable of separating blood into an isolated plasma component and an isolated blood cell component;
- (c) ~~(e)~~—collecting blood from the donor canine animal via the blood collection catheter;
- ~~(d)~~ ~~(d)~~—separating the blood into the isolated plasma component and the isolated blood cell component;
- (e) collecting the isolated plasma component;
- ~~(f)~~ ~~(f)~~—stopping the collecting of blood;
- ~~(g)~~ ~~(g)~~—returning the blood cell component to the donor canine animal; and
- ~~(h)~~ ~~(h)~~—repeating steps (c) – (g).

8-32. (cancelled)

33. (currently amended) A method of producing hyperimmunised canine animal plasma including the steps of:

- (1) selecting a donor canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group;
- (2) administering to the donor canine animal ~~at least one a heat-killed *E. coli*~~ antigen thereby inducing an immune response in said donor canine animal;
- (3) administering to said donor canine animal ~~at least one same a heat-killed *E. coli* antigen(s) administered in step (2)~~ during said immune response; and
- (4) isolating plasma from said donor canine animal wherein said donor canine animal is characterised by a phenotype negative for anti-globulin antibodies.

Applicant: Wilson

Application No.: 10/589,931

Amendment and Response dated November 30, 2009

Reply to Office Action dated May 28, 2009

Docket No.: 1567-7 PCT/US

Page 5

34. (currently amended) The method of claim 33 wherein said donor canine animal is further characterised by a phenotype negative for at least one Dog Erythrocyte Antigen.

35. (currently amended) The method of claim 34 wherein said donor canine animal is further characterised by a phenotype negative for Dog Erythrocyte Antigen 1.1.

36. (currently amended) The method of claim 34 wherein said donor canine animal is further characterised by a phenotype negative for Dog Erythrocyte Antigen 1.2.

37. (currently amended) The method of claim 34 wherein said donor canine animal is further characterised by a phenotype negative for Dog Erythrocyte Antigen 7.

38-50. (cancelled)

51. (currently amended) The method of any one of claims 33-37, 50 wherein the heat-killed *E. coli* antigen is an *E. coli* J5 antigen.

52-54. (cancelled)

55. (withdrawn) Isolated canine animal plasma comprising at least one immunoglobulin capable of binding to a gram negative bacteria or component thereof.

56. (withdrawn) The isolated canine animal plasma of claim 55 wherein said gram negative bacteria or component thereof is *E. coli*.

57. (withdrawn) The isolated canine animal plasma of claim 56 wherein the *E. coli* is *E. coli* J5.

Applicant: Wilson

Application No.: 10/589,931

Amendment and Response dated November 30, 2009

Reply to Office Action dated May 28, 2009

Docket No.: 1567-7 PCT/US

Page 6

58. (withdrawn) The isolated canine animal plasma of claim 57 wherein the component of the *E. coli* is lipopolysaccharide, oligosaccharide and/or a respective component thereof.

59. (withdrawn) The isolated canine animal plasma of claim 58 further comprising at least one immunoglobulin capable of binding an additional canine animal pathogen.

60. (withdrawn) The isolated canine animal plasma of claim 59 wherein the canine animal pathogen is selected from the group consisting of: a virus, parasite and bacteria.

61. (withdrawn) The isolated canine animal plasma of claim 60 wherein the canine animal pathogen is selected from the group consisting of: distemper virus, canine adenovirus type 2 (CAV2), canine parvovirus type 2 (CPV2), canine parainfluenza virus and *Bordetella bronchiseptica*.

62-66. (cancelled)

67. (withdrawn) A method for treating or improving health of a canine animal of a condition including the steps of administering to the canine animal isolated canine animal plasma of claim 55.

68. (withdrawn) The method of claim 67 wherein said condition is selected from the group consisting of: parvovirus infection, lack of passive transfer of antibodies to a canine pup, hypoprotinaemia, glomerulonephritis, shock, fluid therapy, congenital clotting disorders, thrombocytopenia, vitamin K deficiency, haemophilia, disseminated intravascular coagulation, pancreatitis, reduced blood coagulation, infection, surgery, tissue injury and destruction, pyometron, poisoning, snake envenomation, advanced blood loss and severely debilitating infections.

Applicant: Wilson

Application No.: 10/589,931

Amendment and Response dated November 30, 2009

Reply to Office Action dated May 28, 2009

Docket No.: 1567-7 PCT/US

Page 7

69. (withdrawn) The method of claim 68 wherein reduced blood coagulation is a result of poisoning, disseminated intravascular coagulation and/or haemophilia.

70. (withdrawn) The method of claim 69 wherein the isolated canine animal plasma is administered in range of 2-15 mL/Kg weight of the canine animal per hour.

71-72. (cancelled)

73. (new) The method of claim 1, wherein said heat-killed *E. coli* antigen is an *E. coli* J5 antigen.